Beardsley Robert A 4
4 · Galera Therapeutics, Inc. · Filed Nov 12, 2019
Insider Transaction Report
Form 4
Beardsley Robert A
Chief Operating Officer
Transactions
- Conversion
Series A Preferred Stock
2019-11-12−68,907→ 0 total→ Common Stock (13,627 underlying) - Conversion
Series C Preferred Stock
2019-11-12−6,774→ 0 total→ Common Stock (1,339 underlying) - Conversion
Common Stock
2019-11-12+15,361→ 68,191 total - Conversion
Series B Preferred Stock
2019-11-12−2,000→ 0 total→ Common Stock (395 underlying)
Footnotes (1)
- [F1]Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.